glp-1 news today nov 2025 Who Gets the Shot? Access by State GLP-1 trends 2025: real-world data,

Ozempic, Wegovy, Mounjaro, and Zepbound are pretty much household names at this point.

GLP-1 medications like semaglutide and tirzepatide show mixed effects on gastrointestinal symptoms, with potential benefits for some IBS patients but also the risk of worsening symptoms in others

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are desirable for diabetes, especially in patients with overweight/obesity

Some of the dual and triple agonists have already shown initial successes in clinical trials, although the molecular mechanisms underlying their multiplexed pharmacology remain elusive

Learn more and improve your treatment experience.